ClinicalTrials.gg
Status unknownNCT02332122Updated Aug 24, 2015

Detection of Aspergillus Fumigatus and Sensitization in COPD Patients With Bronchiectasis vs Without Bronchiectasis

An observational study in Chronic Obstructive Pulmonary Disease, sponsored by Wim Janssens. Status unknown at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-24.

Sponsored by Wim Janssens · Observational

How we know

The sponsor has not verified this record recently (last verified Aug 2015), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 205 studies in Pulmonary Disease, Chronic Obstructive with a site in Belgium — 13 open to participants now, 17 under way, 5 of them phase 3. Pulmonary Disease, Chronic Obstructive · Belgium.

Planned enrollment
18th of 30
100 · median 150
Started
2015
with 14 others
Observational
30 of 205
2 open now
Registered
127th of 205
by date

Among the 205 studies in Pulmonary Disease, Chronic Obstructive with a site in Belgium, this one is the 18th largest by planned enrollment of the 30 observational ones that give a count, is one of 15 that started in 2015, is one of 30 observational ones, and was the 127th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

13 of the 205 studies in Pulmonary Disease, Chronic Obstructive with a site in Belgium are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Pulmonary Disease, Chronic Obstructive with a site in Belgium, or all of them as a file.
02

Study summary

A single center case-control study with 100 COPD patients will be organized to compare patients with and without bronchiectasis with regard to the presence of Aspergillus in sputum samples, Aspergillus sensitization and vitamin D. Induced sputum samples will be optimized for culture, Aspergillus galatomannan analysis and RT-PCR.

This study is part of a larger project in which we assume that chronic respiratory infection by Aspergillus fumigatus and the accompanying immune response play an important role in the development of bronchiectasis in COPD. We suspect that this mechanism is controlled by vitamin D and it fails by suppression of the vitamin D receptor by Aspergillus fumigatus.

The present study is designed by the Laboratory of pneumology and will be conducted in collaboration with the Laboratory of clinical bacteriology and mycology of the Catholic University of Leuven.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • COPD
  • Chronic Obstructive Pulmonary Disease
  • Aspergillus fumigatus
  • Bronchiectasis
  • Sensitization
  • Vitamin D
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who present in the emergency department with an acute COPD exacerbation (as defined by GOLD executive summary) requiring hospitalization are eligible for this study. Patients should have an established diagnosis of COPD (based on clinical history or pulmonary function test). They will be recruited during their hospital stay in the University Hospital of Leuven.

Additionally, we will include 20 patients with COPD (10 with bronchiectasis versus 10 without) in stable state during their outpatient visits.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Established diagnosis of by medical doctor (based on clinical history or pulmonary function test)
  • Smoking history of at least 10 pack-years
  • CT Thorax available for assessment of bronchiectasis
  • >= 30%

Exclusion criteria

Exclusion Criteria:

  • Mechanical or non-invasive ventilation
  • Other main respiratory diagnosis other than
  • Active mycobacterial disease
  • other than
  • Active cancer treatment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • COPD patients with bronchiectasis

    All patients will receive standard therapy for AECOPD. Additional for this study are: Sputum induction, Skin prick test, Questionnaires

    Procedure: Sputum induction · Procedure: Skin prick test · Other: Questionnaires

  • COPD patients without bronchiectasis

    All patients will receive standard therapy for AECOPD. Additional for this study are: Sputum induction, Skin prick test, Questionnaires

    Procedure: Sputum induction · Procedure: Skin prick test · Other: Questionnaires

Interventions

  • ProcedureSputum induction

    Patients will have to puff 200µg of salbutamol (metered-dose inhaler with spacer device). After 10 minutes FEV1 will be measured with MIR spirobank. If FEV1 is \>= 30% we can safely proceed with sputum induction. An ultrasonic nebulizer will be used to induce sputum. 4% sodiumchloride will be inhaled. Induction will be performed at 5-min intervals until a sample of good quality is obtained. Sodiumchloride of 5% will be used if no good sample is obtained after two intervals with the 4% solution. Maximal time of induction will be 20 minutes. Subjects will spit saliva into one container and rinse the mouth thoroughly with water before coughing sputum into another sterile container. Samples will be refrigerated at 4°C and processed within 24 hours of collection.

  • ProcedureSkin prick test

    Skin Prick Test is a reliable method to diagnose IgE-mediated allergic disease. It is minimally invasive and results are immediately available. Interpretation utilizes the presence and degree of cutaneous reactivity as a surrogate marker for sensitization. A positive control, a negative control and Aspergillus fumigatus will be tested. Location will be Protocol version 1 3/11/2014 marked on the volar aspect of the forearm and drops of each solution will be placed (\>= 2cm between drops). A single-head metal lancet will be pressed through the drop of allergen extract and held against the skin for at least 1 second. A new lancet will be utilized for each drop. A wheal diameter of \>= 3mm is a positive result.

  • OtherQuestionnaires

    MRC: Medical Research Council Scale CAT: COPD Assessment Test SGRQ: Saint George's respiratory questionnaire

06

What researchers measure

Primary outcomes

  1. Bronchiectasis

    Time frame: immediate

Secondary outcomes

  1. Vitamin D

    Time frame: immediate

  2. Prevalence of Aspergillus sensitization

    Time frame: max 12weeks

  3. Prevalence of Aspergillus isolation in sputum

    Time frame: max 12weeks

07

Study locations

1 of 1 sites recruiting
  • UZ Gasthuisberg
    Leuven, Vlaanderen 3000, Belgium
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Dec 2016 and a completion of May 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2015
First posted
Jan 6, 2015
Start
Jan 2015
Primary completionEst.
Dec 2016
CompletionEst.
May 2017
Last update
Aug 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02332122
Lead sponsor
Wim Janssens
Responsible party
Wim Janssens (MD. PhD, KU Leuven) — Sponsor-investigator
First posted
Jan 6, 2015
Start date
Jan 2015
Primary completion
Dec 2016 (estimated)
Completion
May 2017 (estimated)
Last update
Aug 24, 2015

Study contacts

Stephanie Everaerts, MD
Contact
Stephanie.Everaerts@kuleuven.be
016 37 94 92 ext. 0032
Wim Janssens, MD. PhD
Contact
wim.janssens@uzleuven.be
016 34 68 00 ext. 0032
Wim Janssens, MD. PhD
principal investigator · KU Leuven - UZ Leuven

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion